Nayan Eye Centre & Med Invent Devices Pvt. Ltd., Kolkata, India.
Indian J Med Res. 2024;159(3 & 4):379-384. doi: 10.25259/IJMR_519_2024.
Cataract surgery in the eyes, where the pupil does not dilate despite using eye drops, is fraught with vision-threatening complications. About 11 per cent of eyes undergoing cataract surgery have non-dilating, small pupils. The increasing prevalence of benign prostatic hyperplasia (BPH), hypertension, diabetes and medications used for the same are the contributing factors. The recent Food and Drug Administration (FDA) approval for the use of miotic agents in the treatment of presbyopia will lead to a further rise in the number of non-dilating pupils. While pharmacological agents and other methods have been used, mechanical pupil expander devices are the only fail safe option. However, available devices had a steep learning curve and limitations which made them difficult to use, unpredictable and unsafe. With its patented single plane, hexagonal, notches and flanges design, the US FDA registered B-HEX Pupil Expander (Med Invent Devices Pvt. Ltd., India) overcame these limitations and fulfilled an unmet need. The B-HEX is machinable, rapidly produced, consistent, easy to use, safe, and affordable. Despite such advantages, implementation hurdles have restricted its availability to healthcare systems worldwide. Peer acceptance has been steadily growing, with the B-HEX becoming the market leader in India, as evidenced by numerous publications, videos and papers presented at international conferences and comments from opinion leaders endorsing its use. However, impractical regulatory requirements and resource constraints remain a great impediment to the global distribution of this novel invention. This has denied many patients the benefits of a superior and more affordable option. Though value continues to be added to the B-HEX by maintaining a strong intellectual property portfolio with internationally granted Patents and Trademark, increasing its user base, and garnering support from key opinion leaders, only a collaboration with the right partner will help scale up the global reach and make it a leader in the global market.
尽管使用了眼药水,但眼部白内障手术中的瞳孔仍未扩大,这可能会导致威胁视力的并发症。大约有 11%接受白内障手术的眼睛存在瞳孔无法扩大的情况,且这些瞳孔较小。良性前列腺增生症(BPH)、高血压、糖尿病以及用于治疗这些疾病的药物的发病率不断上升,是导致这种情况的部分原因。最近,食品和药物管理局(FDA)批准使用缩瞳剂治疗老花眼,这将导致无法扩大的瞳孔数量进一步增加。虽然已经使用了药理学制剂和其他方法,但机械性瞳孔扩张器是唯一可靠的选择。然而,现有的设备学习曲线陡峭,存在限制,这使得它们难以使用、不可预测且不安全。印度 Med Invent Devices Pvt. Ltd. 公司生产的 B-HEX 瞳孔扩张器(美国食品和药物管理局注册)克服了这些限制,满足了未满足的需求。该设备具有专利的单平面、六边形、凹口和凸缘设计,可机械加工、快速生产、一致性好、易于使用、安全且价格实惠。尽管具有这些优势,但实施障碍限制了其在全球医疗保健系统中的应用。随着越来越多的出版物、国际会议上的视频和论文以及意见领袖的认可,该产品在印度已逐渐成为市场领导者,其在同行中的认可度也在稳步提高。然而,不切实际的监管要求和资源限制仍然是该创新产品在全球推广的巨大障碍。这使许多患者无法受益于这种更优越且更实惠的选择。尽管通过维护具有国际专利和商标的强大知识产权组合、增加用户群以及获得主要意见领袖的支持,不断为 B-HEX 增加价值,但只有与合适的合作伙伴合作,才能扩大其全球影响力,使其成为全球市场的领导者。